21 cases reports on haemangioma of spleen.
The growing activity of hemangioma of spleen keeps unknown. To search theoretical basis for whether to take the operation, this study analyzed clinical data of 21 hemangioma patients, and 16 surgical specimens were analyzed immunohistochemistry of Ki-67, Bcl-2 and vascular endothelial growth factor (VEGF). Both 14 cases of cavernous hemangioma were positive for VEGF, and negative in capillary hemangioma, there was statistical significant difference between two types of hemangioma (P < 0.05). The most tumors had a low expression of Ki-67 with a mean ± standard deviation (SD) of 6.62 ± 6.24%, whereas the mean ± SD of Bcl-2 labeling index was 36.06 ± 19.05%. According to the statistical results, the expression of Ki-67 and Bcl-2 did not correlate with age, gender, tumor size, amount of tumor and angiomatous types. Hemangioma of spleen was one benign tumor with a tendency of slow growth. Therefore, operation should be strictly selected, we recommend observation of patients with small, asymptomatic splenic lesions, which meet the radiologic criteria for hemangiomas.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yuan
Y
Huang
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guangchuan
G
Mu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xingan
X
Qin
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Jinling
J
Lin
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shaosen
S
Li
Biomedical Engineering Center, Beijing University of Technology, Beijing, China.
Yanjun
Y
Zeng
D015415:Biomarkers; D006391:Hemangioma / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000601:surgery; D016896:Treatment Outcome
D015415:Biomarkers; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2